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Acute Heart Failure developed 
as worsening of Chronic Heart 
Failure is associated with increased 
mortality compared to de novo 
cases
Vesna Degoricija1,2, Matias Trbušić1,2, Ines Potočnjak1, Bojana Radulović3, Sanda Dokoza 
Terešak1, Gudrun Pregartner4, Andrea Berghold4, Beate Tiran5 & Saša Frank6,7
Acute heart failure (AHF) emerges either de novo or from worsening of chronic heart failure (CHF). The 
aim of the present study was to evaluate the association between worsening of CHF and mortality 
in AHF patients. Out of 152 included AHF patients, 47 (30.9%) were de novo AHF patients and 105 
(69%) were AHF patients with worsening of CHF. The proportion dying in hospital (19.0% vs. 4.3%, 
p = 0.023) and within 3 months after hospitalization (36.6% vs. 6.7%, p < 0.001) was significantly 
higher in AHF patients with worsening of CHF. Logistic regression analyses also showed a significant 
positive association of AHF emerging as worsening of CHF with hospital mortality [odds ratio (OR) and 
95% confidence interval (CI): 5.29 (1.46–34.10), p = 0.029] and 3-month mortality [8.09 (2.70–35.03), 
p = 0.001]. While the association with hospital mortality was no longer significant after adjusting for 
comorbidities and clinical as well as laboratory parameters known to be associated with mortality 
in heart failure patients, the association with 3-month mortality remained significant. We conclude 
that compared to de novo AHF, AHF evolved from worsening of CHF is a more severe condition and is 
associated with increased mortality.
Heart failure (HF) is a frequent cause of death and disability worldwide1. According to the European Society 
of Cardiology (ESC) HF denotes an abnormality of the cardiac structure and function, resulting in failure of 
the heart to deliver oxygen at a rate commensurate with the requirements of the metabolizing tissues2,3. Acute 
heart failure (AHF) denotes the rapid onset, or a massive exaggeration of existing symptoms and signs of HF3. 
Accordingly, there are patients with de novo AHF and those with AHF as a consequence of the worsening of 
Chronic Heart Failure (CHF).
HF is a complex syndrome with a versatile underlying pathophysiology, highlighted by disturbed hemod-
ynamics and a deranged metabolism4. Insufficient tissue perfusion due to impaired performance of the failing 
heart as well as tissue congestion due to venous volume overload, a consequence of right-sided HF, cause impaired 
intestinal nutrient absorption, diminished biosynthetic capacity of the liver5, and worsened renal function in 
HF6,7. Consequently, the decreased serum levels of cholesterol, increased concentrations of urea and creatinine, 
as well as wasting and chronic inflammation reflect the poor overall status associated with an increased mortality 
rate in HF patients8.
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Considering the persistent hemodynamic and metabolic burden imposed on CHF patients we hypothesized 
that the clinical and laboratory characteristics are worse and the mortality rate higher in AHF patients with 
worsening of CHF compared to de novo AHF patients. Therefore, we compared the clinical and laboratory char-
acteristics of patients with worsening of CHF with those of de novo AHF patients and evaluated the association 
between worsening of CHF and mortality in AHF patients.
Results
Clinical characteristics. The patients’ baseline characteristics have been described elsewhere9 and are 
shown in Table 1. Out of 152 included patients, 105 (69.1%) were patients with worsening of CHF and 47 (30.9%) 
were de novo AHF patients. As seen in Table 1, both groups were similar regarding age, sex, smoking status, body 
mass index (BMI) and New York Heart Association (NYHA) functional classification. Compared to de novo AHF 
patients, patients with worsening of CHF had a significantly lower mean arterial pressure (MAP) and heart rate 
(Table 1), whereas respiratory rate and the incidence of dyspnoea and ortopnoea were similar in both groups 
(Supplementary Table 1). Venous congestion, a consequence of right-sided HF, was more frequent in patients 
with worsening of CHF; this was exemplified by a significantly higher incidence of jugular venous distension 
(JVD), enlarged liver, and peripheral edema (Table 1). The incidence of ascites was higher, albeit not statistically 
significantly in patients with worsening of CHF compared to de novo AHF patients (Table 1). Furthermore, sys-
tolic pulmonary artery pressure (SPAP) was significantly higher in patients with worsening of CHF compared to 
de novo AHF patients, whereas ejection fraction (EF) (Table 1), the incidence of aortic insufficiency, aortic steno-
sis, and dilatation of right or left ventricle did not differ significantly between the groups (Supplementary Table 1).
Regarding comorbidities, the incidence of chronic obstructive pulmonary disease (COPD), chronic kidney 
disease (CKD), and cardiomyopathy (CM) were significantly higher, and the incidence of acute coronary syn-
drome (ACS) was significantly lower in AHF patients with worsening of CHF compared to de novo AHF patients 
(Supplementary Table 2). In contrast, the incidence of hyperlipidemia, hypercholesterolemia, hypertension, type 
2 diabetes mellitus (T2DM) as well as coronary and peripheral atherosclerosis was similar in both groups.
Laboratory parameters. The markers of kidney function urea and creatinine, were significantly higher 
and glomerular filtration rate (GFR) significantly lower in patients with worsening of CHF compared to de novo 
AHF patients (Table 2). While the N-terminal pro-Brain Natriuretic Peptide (NT-proBNP) and interleukin-6 
(IL-6) levels were significantly higher, the levels of alanine aminotransferase (ALT), total cholesterol, low-density 
lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol, as well as leukocytes, and platelets 
were significantly lower in patients with worsening of CHF compared to de novo AHF patients (Table 2). Levels of 
aspartate transaminase (AST), C-reactive protein (CRP), triglycerides and erythrocytes did not differ significantly 
between groups (Table 2). While the levels of total serum protein and albumin, as well as glucose, sodium, and 
potassium were not significantly different between groups, the chloride levels were significantly lower in patients 
with worsening of CHF compared to de novo AHF patients (Supplementary Table 3).
All AHF patients
(N = 152)
De novo AHF
(N = 47)
Worsening of CHF
(N = 105) p-value
Age (years) 77.3 (45.5–96.7) 75.7 (45.5–93.0) 77.5 (50.6–96.7) 0.312
Female 79 (52.0%) 20 (42.6%) 59 (56.2%) 0.160
BMI (kg/m2) 28.5 (16.3–43.5) 30.1 (16.3–38.6) 27.7 (17.1–43.5) 0.113
Weight (kg) 80.0 (40.0–144.0) 89.0 (50.0–125.0) 79.0 (40.0–144.0) 0.042
Smoking 38 (25.0%) 15 (31.9%) 23 (21.9%) 0.225
NYHA class 0.124
2 11 (7.2%) 6 (12.8%) 5 (4.8%)
3 83 (54.6%) 27 (57.4%) 56 (53.3%)
4 58 (38.2%) 14 (29.8%) 44 (41.9%)
MAP (mmHg) 103.3 (53.3–160.0) 110.0 (70.0–160.0) 100.0 (53.3–156.7) 0.007
Heart rate (beats/min) 100.0 (36.0–160.0) 110.0 (36.0–160.0) 99.0 (50.0–150.0) 0.041
JVD 52 (34.2%) 10 (21.3%) 42 (40.0%) 0.027
Enlarged liver 53 (34.9%) 9 (19.1%) 44 (41.9%) 0.009
Peripheral edema 105 (69.1%) 26 (55.3%) 79 (75.2%) 0.022
Ascites 21 (13.8%) 4 (8.5%) 17 (16.2%) 0.309
EF (%) 45.0 (20.0–70.0) 45.0 (20.0–65.0) 41.0 (20.0–70.0) 0.677
SPAP (mmHg) 45.0 (35.0–80.0) 40.0 (35.0–60.0) 47.5 (35.0–80.0) 0.002
Table 1. Baseline characteristics, vital signs and symptoms of AHF patients with worsening of CHF vs. de 
novo AHF patients. Data are presented as n (%) or as median and range (minimum to maximum). Differences 
between AHF patients with worsening of CHF and de novo AHF patients were tested with Fisher’s exact test or 
the Mann-Whitney U test, respectively. AHF, acute heart failure; BMI, body mass index; CHF, chronic heart 
failure; EF, ejection fraction; JVD, jugular venous distension; MAP, mean arterial pressure; NYHA, New York 
Heart Association functional classification; SPAP, systolic pulmonary artery pressure.
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Mortality. Significantly more patients with AHF caused by worsening of CHF died in the hospital as well 
as within 3 months after hospitalization compared to de novo AHF patients (Table 3). In line with this, the uni-
variable logistic regression analyses showed a significant positive association of worsening of CHF with hospital 
and 3-month mortality (Table 4). While this association did not remain significant for in-hospital mortality after 
adjusting for age, sex, BMI, NT-proBNP, MAP, GFR, and either urea, IL-6, and LDL cholesterol, or COPD, CKD, 
CM, ACS, and NYHA, the adjustment did not qualitatively change the results for 3-month mortality (Table 4).
Discussion
The present study clearly shows that AHF developed from CHF represents a more severe condition that is associ-
ated with higher mortality when compared to de novo AHF.
Compared to de novo AHF patients, AHF patients with worsening of CHF presented with markedly higher 
concentrations of NT-proBNP, a marker of heart congestion and elevated left-sided filling pressure10, indicating a 
more pronounced left ventricular dysfunction, accompanied by a lower MAP and higher SPAP and in turn, more 
severe right-sided HF with consequently more severe venous congestion.
Interestingly, despite a higher incidence of JVD, enlarged liver and peripheral edema, the body weight in AHF 
patients with worsening of CHF was significantly lower than in de novo AHF patients. This finding most probably 
reflects a more pronounced impairment of the intestinal absorption of nutrients due to a more severe intestinal 
edema, as well as a more severe chronic inflammation, the postulated common link between CHF, wasting syn-
drome and hypoalbuminemia8,11,12. In line with this, our AHF patients with worsening of CHF had lower serum 
levels of albumin (albeit not statistically significant) and significantly higher concentrations of IL-6 when com-
pared to de novo AHF patients.
It is generally accepted that the augmented translocation of bacterial endotoxins from the edematous intestine 
into the circulation13 as well as insufficient binding and neutralization of endotoxines by circulating lipoproteins, 
whose levels are decreased in HF14,15, underlie the persistent inflammatory response in HF16. Additionally, the 
pro-inflammatory activation of venous endothelial cells by circumferential stretch due to congestion contributes 
to the chronic inflammation in HF17. Accordingly, lower serum levels of LDL cholesterol and HDL cholesterol 
together with a more severe congestion, in patients with worsening of CHF compared to de novo AHF patients 
may well explain the more pronounced inflammatory response, reflected by higher IL-6 levels.
All AHF patients
(N = 152)
De novo AHF
(N = 47)
Worsening of CHF
(N = 105) p-value
GFR (ml/min/1.73 m2) 50.9 (15–0–105.7) 58.8 (20.0–105.7) 45.3 (15.0–104.8) 0.001
Urea (mmol/L) 8.0 (3.0–64.0) 7.0 (3.0–64.0) 9.0 (3.0–41.0) 0.003
Creatinine (µmol/L) 106.0 (53.0–273.0) 100.0 (53.0–255.0) 117.5 (59.0–273.0) 0.006
NT-proBNP (ng/mL) 9570 (171–70000) 4465 (171–70000) 12434 (291–70000) <0.001
ALT (U/L) 23.0 (6.0–623.0) 25.0 (6.0–623.0) 21.0 (7.0–556.0) 0.034
AST (U/L) 27.0 (10.0–666.0) 28.0 (11.0–666.0) 27.0 (10.0–487.0) 0.536
IL-6 (pg/mL) 19.8 (0.4–300.0) 15.6 (0.4–300.0) 24.3 (1.2–300.0) 0.005
CRP (µg/mL) 9.4 (0.2–247.4) 5.7 (0.2–247.4) 10.6 (0.4–169.0) 0.189
Total cholesterol (mmol/L) 3.8 (1.7–9.1) 4.4 (2.5–9.1) 3.8 (1.7–7.7) 0.004
LDL cholesterol (mmol/L) 2.3 (0.8–6.3) 2.6 (1.3–6.3) 2.1 (0.8–6.0) 0.004
HDL cholesterol (mmol/L) 1.0 (0.3–3.6) 1.0 (0.4–1.9) 0.9 (0.3–3.6) 0.039
Triglycerides (mmol/L) 1.1 (0.5–4.3) 1.1 (0.6–4.3) 1.0 (0.5–3.2) 0.390
Erythrocytes (x 109/L) 4.6 (2.5–6.6) 4.6 (3.6–5.9) 4.6 (2.5–6.6) 0.938
Leukocytes (x 109/L) 9.7 (3.1–48.9) 11.2 (4.2–21.5) 9.4 (3.1–48.9) 0.017
Platelets (x 1012/L) 216.5 (61.0–999.0) 247.0 (71.0–999.0) 202.0 (61.0–444.0) 0.002
Table 2. Laboratory parameters of AHF patients with worsening of CHF vs. de novo AHF patients. Data are 
presented as median and range (minimum to maximum). Differences between AHF patients with worsening 
of CHF and de novo AHF patients were tested with the Mann-Whitney U test. ALT, alanine aminotransferase; 
AST, aspartate aminotransferase; AHF, acute heart failure; CHF, chronic heart failure; CRP, C-reactive 
protein; GFR, glomerular filtration rate; IL-6, interleukin-6; LDL, low-density lipoprotein; HDL, high-density 
lipoprotein; NT-proBNP, N-terminal pro brain natriuretic peptide.
All AHF patients
(N = 152)
De novo AHF
(N = 47)
Worsening of
CHF (N = 105) p-value
Hospital mortality 22 (14.5%) 2 (4.3%) 20 (19.0%) 0.023
3-month mortality* 40 (27.4%) 3 (6.7%) 37 (36.6%) <0.001
Table 3. Mortality rate of AHF patients with worsening of CHF vs. de novo AHF patients. *N = 146 
observations (45 de novo AHF, 101 worsening of CHF) available. Data are presented as n (%). Differences 
between AHF patients with worsening of CHF and de novo AHF patients were tested with Fisher’s exact test; 
significant differences are depicted in bold. AHF, acute heart failure; CHF, chronic heart failure.
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The augmented inflammatory response, which is known to promote the formation and clearance of leukocyte - 
platelet complexes18,19, is most likely responsible for the lower leukocyte and platelet levels in our AHF patients 
with worsening of CHF.
It is well established that decreased cholesterol and lipoprotein serum levels are strongly and independently 
associated with increased mortality in HF8,14. In contrast to total, LDL, and HDL cholesterol, which were signifi-
cantly lower in patients with worsening of CHF, triglyceride levels were similar in both studied groups.
Serum levels of lipids and lipoproteins are determined by their intestinal absorption, hepatic synthesis, and 
removal from the circulation by various catabolic routes. Accordingly, modulation of these physiological pro-
cesses by the underlying AHF pathophysiology, such as congestion, which was more severe in AHF patients with 
worsening of CHF, may explain the different levels of total, LDL, and HDL cholesterol in the studied groups. 
Similar triglyceride levels in the two studied groups may indicate either that the triglyceride synthesis is not 
affected by the underlying AHF pathophysiology or that the decreased triglyceride synthesis is counterbalanced 
by a likewise decreased triglyceride catabolism. The latter possibility is likely, because lipoprotein lipase, a serum 
enzyme responsible for triglyceride degradation, is decreased by inflammation20, which indeed was more severe 
in AHF patients with worsening of CHF than in de novo AHF patients.
Renal dysfunction, also a strong predictor of mortality in HF21,22, was more pronounced in our AHF patients 
with worsening of CHF than in de novo AHF patients. This was reflected by a markedly decreased GFR and 
concomitantly increased serum levels of urea and creatinine. The reduction in GFR may be due to several fac-
tors including kidney hypoperfusion23, renal co-morbidities24, renal venous congestion25,26, or inflammatory 
cytokines such as IL-627. Accordingly, a higher incidence of CKD, together with a more severe venous congestion 
and a more pronounced inflammatory response, as well as higher serum levels of NT-proBNP, an established 
predictor of worsening renal function in CHF28, may well explain the more severe impairment of renal function 
in our AHF patients with worsening of CHF compared to de novo AHF patients.
Besides their deleterious effects on the kidneys, inflammatory cytokines such as IL-6 exert a direct detrimental 
effect on the myocardial structure and function by promoting oxidative stress and endothelial dysfunction, thus 
contributing to the progression of HF29. Therefore, a more pronounced inflammatory state, reflected by higher 
IL-6 levels, seems to be an important underlying pathophysiology responsible for worse clinical status of our AHF 
patients with worsening of CHF compared to de novo AHF patients.
The above-mentioned differences between the groups regarding the clinical characteristics observed in our 
AHF patients with worsening of CHF translated into a higher mortality rate, whereby the impact on 3-month 
mortality was more pronounced than the impact on hospital mortality. This is in line with two recent reports 
showing a strong association of the chronicity of HF with 6-month and 3-year mortality, but only a weak associa-
tion with 1-month mortality30,31. In the present study, the strong association of worsening of CHF with 3-month 
mortality was weakened, but remained significant upon adjustment for comorbidities and established risk factors 
in HF8,32,33. This implies that other features inherent to this group of patients underlie their increased mortality 
compared to de novo AHF patients.
There are several limitations to our present study: The design precludes conclusions on the pathophysiological 
mechanisms in terms of cause and consequence, or temporal development and onset of signs, and symptoms 
associated with worsened status and increased mortality. Furthermore, our data do not facilitate the examination 
whether the duration of HF chronicity affects mortality rates. Finally, the limited number of participants in this 
monocentric study influences the statistical power of our analyses. Therefore, further large studies are needed to 
confirm our results.
Based on our results, we conclude that AHF developed from CHF is a more severe condition than de novo 
AHF and is associated with higher mortality rates.
OR (95% CI) p-value Events/N
Hospital mortality
unadjusted 5.29 (1.46–34.10) 0.029 22/152
adjusted* 1.59 (1.33–11.64) 0.593 20/140
adjusted** 3.38 (0.65–27.86) 0.188 20/140
3-month mortality
unadjusted 8.09 (2.70–35.03) 0.001 40/146
adjusted* 4.35 (1.20–21.72) 0.040 37/134
adjusted** 5.90 (1.53–31.68) 0.019 37/134
Table 4. Logistic regression analyses to assess the influence of the AHF class (worsening of CHF compared to 
de novo AHF) on hospital and 3-month mortality. *Model was adjusted for age, sex, BMI, NT-proBNP, MAP, 
GFR, urea, IL-6, and LDL cholesterol. **Model was adjusted for age, sex, BMI, NT-proBNP, MAP, GFR, COPD, 
CKD, CM, ACS, NYHA. Data presented are ORs and 95% CIs for AHF as worsening of CHF vs. de novo AHF 
(reference) as well as the number of events and observations left in the analysis. ACS, acute coronary syndrome; 
AHF, acute heart failure; BMI, body mass index; CHF, chronic heart failure; CI, confidence interval; CKD, 
chronic kidney disease; CM, cardiomyopathy; COPD, chronic obstructive pulmonary disease; GFR, glomerular 
filtration rate; IL-6, interleukin-6; LDL, low-density lipoprotein; MAP, mean arterial pressure; NT-proBNP, 
N-terminal brain natriuretic peptide; OR, odds ratio.
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Methods
Study design and patients. Study design, inclusion and exclusion criteria as well as patient characteris-
tics for our AHF cohort have been reported previously9,34. In short, we performed a prospective observational 
study on hospitalized patients with AHF in Zagreb, Croatia, between 2013 and 2015. Written informed consent 
was obtained from each patient and the study, which was approved by the Ethics Committees of the University 
Hospital Centre Sisters of Charity, Zagreb, Croatia and the Medical University of Graz, Austria, was conducted 
in adherence to the ethical guidelines of the Declaration of Helsinki35. All patients were treated according to the 
ESC Guidelines for AHF3,36.
Measurements of SPAP. SPAP was approximated the tricuspid valve velocity, estimated central vein pres-
sure (resembling right atrium pressure), and Bernoulli equation from a Doppler echocardiography.
Laboratory procedures. The collection of blood samples, standard laboratory methods, and the determi-
nation of the NT-proBNP concentration have been described in our previous reports on our AHF cohort34,37. The 
levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were determined with the Abbott 
Architect c8000 (Chicago, IL, USA).
Statistical analyses. Categorical data are shown as absolute and relative frequencies, whereas continuous data 
are summarized as median and range (minimum to maximum) due to the skewed distribution of many of the lab-
oratory parameters. Patients with de novo AHF and with worsening of CHF were compared by Mann-Whitney U 
test or Fisher’s exact test. The impact of worsening of CHF as compared to de novo AHF on hospital and 3-month 
mortality was assessed by logistic regression analysis. In addition to a univariable model, we also adjusted for age, sex, 
BMI, NT-proBNP, GFR, MAP, urea, IL-6, and LDL cholesterol, as well as for age, sex, BMI, NT-proBNP, MAP, GFR, 
COPD, CKD, CM, ACS, and NYHA, the comorbidities as well as clinical and laboratory parameters known to be 
associated with mortality in HF patients. We checked the variance inflation factor to prevent multi-collinearity among 
the covariates. Results are presented as odds ratios (OR) with the respective 95% confidence interval (CI). All analyses 
are exploratory and a p-value of <0.05 was considered significant. R version 3.4.2. was used for all statistical analyses.
Data availability. All data generated or analysed during this study are included in this manuscript and 
accompanied Supplementary material.
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